Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the European Commission (EC) has designated ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Management Comments

Ionis Pharmaceuticals (IONS) PT Raised to $36 at Leerink PartnersAugust 1, 2016 3:30 PM Ionis Pharmaceuticals (IONS) PT Raised to $64 at Needham & Company as ENDEAR Study Halted Early for EfficacyAugust 1, 2016 12:20 PM Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy (FPL)July 28, 2016 4:00 PM